Literature DB >> 7850269

Thr4Lys rhodopsin mutation is associated with autosomal dominant retinitis pigmentosa of the cone-rod type in a small Dutch family.

L I van den Born1, M J van Schooneveld, L A de Jong, F C Riemslag, P T de Jong, A Gal, E M Bleeker-Wagemakers.   

Abstract

A mother and daughter with autosomal dominant retinitis pigmentosa (adRP) were found to carry a cytosine-to-adenine transversion mutation at codon 4 of the rhodopsin gene. This mutation predicts a substitution of lysine for threonine at one of the glycosylation sites in the rhodopsin molecule (Thr4Lys). Both patients presented with a similar phenotype including a tigroid pattern of the posterior pole and a regional predilection for degenerative pigmentary changes in the inferior retina with corresponding visual field defects. The electroretinographic pattern was suggestive of RP of the cone-rod type. This report documents the clinical findings associated with this defined mutation of the rhodopsin gene.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7850269     DOI: 10.3109/13816819409098864

Source DB:  PubMed          Journal:  Ophthalmic Genet        ISSN: 1381-6810            Impact factor:   1.803


  15 in total

Review 1.  Light and inherited retinal degeneration.

Authors:  D M Paskowitz; M M LaVail; J L Duncan
Journal:  Br J Ophthalmol       Date:  2006-05-17       Impact factor: 4.638

2.  N-linked glycosylation of protease-activated receptor-1 at extracellular loop 2 regulates G-protein signaling bias.

Authors:  Antonio G Soto; Thomas H Smith; Buxin Chen; Supriyo Bhattacharya; Isabel Canto Cordova; Terry Kenakin; Nagarajan Vaidehi; JoAnn Trejo
Journal:  Proc Natl Acad Sci U S A       Date:  2015-06-22       Impact factor: 11.205

3.  Photoactivation-induced instability of rhodopsin mutants T4K and T17M in rod outer segments underlies retinal degeneration in X. laevis transgenic models of retinitis pigmentosa.

Authors:  Beatrice M Tam; Syed M Noorwez; Shalesh Kaushal; Masahiro Kono; Orson L Moritz
Journal:  J Neurosci       Date:  2014-10-01       Impact factor: 6.167

4.  Steroids do not prevent photoreceptor degeneration in the light-exposed T4R rhodopsin mutant dog retina irrespective of AP-1 inhibition.

Authors:  Danian Gu; William A Beltran; Sue Pearce-Kelling; Zexiao Li; Gregory M Acland; Gustavo D Aguirre
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-02-21       Impact factor: 4.799

Review 5.  Finding and interpreting genetic variations that are important to ophthalmologists.

Authors:  Edwin M Stone
Journal:  Trans Am Ophthalmol Soc       Date:  2003

Review 6.  Rhodopsin: the functional significance of asn-linked glycosylation and other post-translational modifications.

Authors:  Anne R Murray; Steven J Fliesler; Muayyad R Al-Ubaidi
Journal:  Ophthalmic Genet       Date:  2009-09       Impact factor: 1.803

7.  A naturally occurring mutation of the opsin gene (T4R) in dogs affects glycosylation and stability of the G protein-coupled receptor.

Authors:  Li Zhu; Geeng-Fu Jang; Beata Jastrzebska; Slawomir Filipek; Susan E Pearce-Kelling; Gustavo D Aguirre; Ronald E Stenkamp; Gregory M Acland; Krzysztof Palczewski
Journal:  J Biol Chem       Date:  2004-09-30       Impact factor: 5.157

8.  Clinical light exposure, photoreceptor degeneration, and AP-1 activation: a cell death or cell survival signal in the rhodopsin mutant retina?

Authors:  Danian Gu; William A Beltran; Zexiao Li; Gregory M Acland; Gustavo D Aguirre
Journal:  Invest Ophthalmol Vis Sci       Date:  2007-11       Impact factor: 4.799

9.  Retinal specific measurement of dark-adapted visual function: validation of a modified microperimeter.

Authors:  Michael D Crossland; Vy A Luong; Gary S Rubin; Fred W Fitzke
Journal:  BMC Ophthalmol       Date:  2011-02-08       Impact factor: 2.209

10.  Endoplasmic reticulum microenvironment and conserved histidines govern ELOVL4 fatty acid elongase activity.

Authors:  Sreemathi Logan; Martin-Paul Agbaga; Michael D Chan; Richard S Brush; Robert E Anderson
Journal:  J Lipid Res       Date:  2014-02-25       Impact factor: 5.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.